Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Roles of astrocytes in synaptic transmission and plasticity

ASTROSYN

The research area of this proposal is Life Science at the intersection of neuroscience, pharmacology and physiology. In the central nervous system (CNS), astrocytes are both numerous and complex. They contact most other cell types in the CNS, and the processes of a single astrocyte can envelop as many as 140,000 synapses. Thus, these cells are...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Significance of TDP-43 in the population in relation to dementia

STPRD

The incidence and prevalence of dementia is rising as the world-wide population ages. Determining biomarkers for the early detection of underlying biology that will predict dementia progression reliably or, the monitoring of biological processes once present to track progression and treatment is necessary. Furthermore, these biomarkers will aid in...

Funding Programme
Start Date
End Date
Total Funding
€ 182 485
European Countries Involved

Simulation of the Kinetics and Inverse Problem
for the Protein PolymERization
in Amyloid Diseases (Prion, Alzheimer’s)

SKIPPERAD

Amyloid diseases are of increasing concern in our aging society. These diseases all involve the aggregation of misfolded proteins, called amyloid, which are specific for each disease (PrP for Prion, Abeta for Alzheimer's). When misfolded these proteins propagate the abnormal configuration and aggregate to others, forming very long polymers also...

Funding Programme
Start Date
End Date
Total Funding
€ 1 203 569
European Countries Involved

siRNA-based therapy for cerebral tauopathies

SITAU

Neurodegenerative disorders are an increasing healthcare problem. Many of these diseases are characterized by aggregation of proteins, which leads to neuronal dysregulation and cell death. Neurofibrillary tangles, pathological aggregates of tau protein, are the characteristic neuropathological stigmata defining a group of disorders termed...

Funding Programme
Start Date
End Date
Total Funding
€ 158 695
European Countries Involved

Small molecule stabilizers of 14-3-3 Protein-Protein Interactions as novel drugs in cancer and neurodegenerative diseases

14-3-3Stabs

The objective of the application is the development and characterization of small molecule stabilizers of protein-protein interactions (“Molecular Glues”) as a novel class of biological tool compounds and potential therapeutic drugs for the treatment of cancer as well as Alzheimer’s and Parkinson’s Disease, respectively. As biological targets we...

Funding Programme
Start Date
End Date
Total Funding
€ 2 008 622
European Countries Involved

Space coding in hippocampo-entorhinal neuronal assemblies

SPACEBRAIN

Despite impressive advances in almost every field of neuroscience, our insights into brain function remain largely confined to its building blocks at the microscopic level, and to phenomenological descriptions at the macroscopic level. Understanding how complex mental functions originate from electrical and chemical processes in brain cells...

Funding Programme
Start Date
End Date
Total Funding
€ 7 996 767
European Countries Involved

Structural and biochemical basis of protein amyloid evolution

STAMYEV

Protein misfolding and aggregation into amyloid fibrils is a hallmark of serious diseases such as Alzheimer´s, Familial Amyloidotic Polyneuropathy (FAP) and atherosclerosis. Amyloid fibrils can also be biologically functional. Bacterial and fungal amyloids are proposed to form a prominent protein fold early in evolution. It is unclear why many...

Funding Programme
Start Date
End Date
Total Funding
€ 328 141
European Countries Involved

Structure and function of γ-secretase studied by single particle cryo-electron microscopy

γsecretase structure

The γ-secretase intramembrane protease complex plays a critical role in multiple cellular processes including Notch signaling and secretion of amyloid β peptides, the accumulation of which causes Alzheimer’s disease (AD). The enzymatic activity of γ-secretase is, therefore, a prime target for intervention in AD and is of major interest. Yet...

Funding Programme
Start Date
End Date
Total Funding
€ 173 000
European Countries Involved

Study and Identification of ADAM10 as Neuronal α-secretase in relation to Alzheimer’s disease

ADAMNEURON

With life expectancy increasing rapidly in our Western world, Alzheimer’s disease (AD), a progressive neurodegenerative disorder resulting in dementia, is becoming more common, however no cures or effective treatments are currently available. The neurotoxic amyloid-β (Aβ) peptide appears central to AD pathogenesis, and is generated by β- and γ...

Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Study of the aging-related changes of the gamma-secretase complex and evaluation to what extent those contribute to amyloid accumulation in sporadic Alzheimer’s disease

Γ-SECRETASE AGING

Alzheimer’s disease (AD) is the most common form of dementia. The main hallmark of AD is presence of the extraneuronal senile plaques composed of amyloid beta-peptide (Aβ). Aβ is produced when a transmembrane glycoprotein called Amyloid Precursor Protein (APP) is consecutively cleaved by two proteases: the γ-secretase and the β-secretase. γ...

Funding Programme
Start Date
End Date
Total Funding
€ 160 100
European Countries Involved

SUstainable PROduction of GALanthamine by both in vitro and agricultural crops of highly galanthamine-containing plants

SUPROGAL

Galanthamine is an alkaloid produced exclusively by plants of the family Amaryllidaceae, mainly belonging to the genus Galanthus, Leucojum and Narcissus. Owing to its acetylcholinesterase inhibitory activity, galanthamine is used and marketed for the treatment of the Alzheimer’s disease, among others. Although it is obtained by organic synthesis...

Funding Programme
Start Date
End Date
Total Funding
€ 1 343 680
European Countries Involved

The functional significance of soluble amyloid beta (Abeta) oligomers for learning and memory deficits in Alzheimer's disease

ABETACOGNITION

Alzheimer’s disease (AD) is characterised by a gradual cognitive decline, which initially affects learning and memory, and gradually impairs other cognitive functions. Despite considerable scientific effort, the cause and pathogenesis of AD is still unknown. Recent in vitro studies suggest that the destruction of synapses by soluble aggregates of...

Funding Programme
Start Date
End Date
Total Funding
€ 161 661
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).